Form 4: Moderna Insider Trades: CLO Shannon Klinger Buys and Sells Stock

Moderna's Chief Legal Officer, Shannon Klinger, engaged in a series of stock transactions, including purchases and sales, under a Rule 10b5-1 trading plan.

Summary

• Shannon Klinger, Chief Legal Officer at Moderna, Inc., executed several stock transactions on June 4th and June 5th, 2026.
• These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on September 9, 2025.
• On June 4, 2026, Klinger acquired 3,471 shares of common stock at a price of $30.96 per share and sold 3,471 shares at $50 per share.
• On June 5, 2026, Klinger acquired 11,798 restricted stock units (RSUs) and sold 5,705 shares at $51.59 per share.
• Following these transactions, Klinger beneficially owns 79,266 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, reflecting routine insider trading activity under a pre-arranged plan rather than a strong signal of company performance or outlook.

Positives

• The transactions were executed under a Rule 10b5-1 trading plan, indicating pre-planned and potentially less market-sensitive trading activity.
• Acquisition of shares at a lower price ($30.96) and sale at a higher price ($50) on June 4th suggests a profitable trade within the plan.
• Acquisition of restricted stock units on June 5th indicates continued equity participation and potential future value.

Negatives

• Sale of 3,471 shares at $50 on June 4th and 5,705 shares at $51.59 on June 5th represents a reduction in direct beneficial ownership.
• Withholding of shares to cover tax obligations on the vesting of RSUs, while standard, reduces the net shares received by the reporting person.

Risks

• The Rule 10b5-1 plan itself is subject to regulatory scrutiny and potential changes in market conditions could impact the effectiveness of such plans.
• Future vesting of RSUs and stock options is contingent on continued employment and company performance.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding future financial performance. However, the continued vesting of stock options and restricted stock units implies ongoing equity awards tied to company performance and employee tenure.

Industry Context

StockSavvy.ai notes that insider transactions under Rule 10b5-1 plans are common for executives seeking to diversify holdings or manage personal finances while adhering to insider trading regulations. The specific buy and sell activity by Moderna's Chief Legal Officer provides insight into internal confidence and liquidity management.

Stakeholder Impact

• Shareholders: The transactions do not directly indicate a change in the company's overall financial health but reflect an executive's personal financial management.
• Employees: The vesting of RSUs and options for management can be seen as a positive incentive, aligning executive interests with company performance.
• Management: Shannon Klinger is managing her personal equity holdings through a structured plan.

Next Steps

• Continued vesting of stock options and restricted stock units as per the terms of the awards.
• Potential future transactions under the Rule 10b5-1 plan, depending on its terms and market conditions.

Key Dates

Keywords

Moderna, MRNA, Form 4, Insider Trading, Rule 10b5-1, Stock Transactions, Shannon Klinger, Chief Legal Officer, Restricted Stock Units, Stock Options